1. Home
  2. VANI vs ITIC Comparison

VANI vs ITIC Comparison

Compare VANI & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vivani Medical Inc. (DE)

VANI

Vivani Medical Inc. (DE)

HOLD

Current Price

$1.40

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Logo Investors Title Company

ITIC

Investors Title Company

N/A

Current Price

$287.45

Market Cap

546.2M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
VANI
ITIC
Founded
1998
1972
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Specialty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
119.0M
546.2M
IPO Year
2014
1995

Fundamental Metrics

Financial Performance
Metric
VANI
ITIC
Price
$1.40
$287.45
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.50
N/A
AVG Volume (30 Days)
166.9K
48.4K
Earning Date
05-14-2026
05-04-2026
Dividend Yield
N/A
4.43%
EPS Growth
N/A
13.02
EPS
N/A
10.93
Revenue
$4,000,000.00
$272,755,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$26.36
Revenue Growth
N/A
5.60
52 Week Low
$0.92
$209.75
52 Week High
$1.92
$297.99

Technical Indicators

Market Signals
Indicator
VANI
ITIC
Relative Strength Index (RSI) 54.30 54.26
Support Level $1.24 $275.85
Resistance Level $1.55 $296.60
Average True Range (ATR) 0.08 8.19
MACD 0.00 -0.72
Stochastic Oscillator 47.60 55.88

Price Performance

Historical Comparison
VANI
ITIC

About VANI Vivani Medical Inc. (DE)

Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.

About ITIC Investors Title Company

Investors Title Co operates in the title insurance and exchange services sectors. The Company has two reportable segments. The Company's primary business activity, and one of its reportable operating segments, is the issuance of residential and commercial title insurance through ITIC and NITIC. The company's second reportable operating segment is providing tax-deferred real property exchange services through its subsidiaries, Investors Title Exchange Corporation (ITEC) and Investors Title Accommodation Corporation (ITAC).

Share on Social Networks: